Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin(Vall d'Hebron Institute of Oncology), Anna V. Tinker(BC Cancer Agency), Bhavana Pothuri(NYU Langone Health), Renaud Sabatier(Centre National de la Recherche Scientifique), Valentina Boni, David M. O’Malley(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer Veneris, Grace Antony(University of Hertfordshire), Sharad Ghamande(Augusta University Health), Joanna Pikiel(Chemotherapy Foundation), Yuping Dong(Innsbruck Medical University), Rowan Miller(University College Hospital), Susana Banerjee(Royal Marsden NHS Foundation Trust), Lucy Gilbert(McGill University Health Centre), Jubilee Brown(Levine Cancer Institute), Ninad Dewal, Mansoor Raza Mirza(Copenhagen University Hospital), Eleftherios Zografos, Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Cara Mathews(Brown University)
Cited by 80
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
|International Journal of Gynecological Cancer|2015|757